🎁 Exclusive for PinkWalk participants

FREE stool-based colorectal screening for 50 participants

This PinkWalk is more than a walk — it is a reminder that early detection can change outcomes.

As participants come together on 3 October 2026 to raise awareness about cancer, Novala Biotech and Center for American Medical Specialist (CAMS) are extending the message of prevention beyond breast cancer awareness to another major but often silent health concern: colorectal cancer.

Many colorectal cancers develop gradually from precancerous polyps. In the early stages, there may be no obvious symptoms, but very small amounts of blood can sometimes be present in the stool before they are visible to the eye.

That is where stool-based screening can help.

As part of the PinkWalk cancer-awareness initiative, 50 selected participants will receive a FREE FIT-based stool screening test.

A simple stool sample can help detect hidden gastrointestinal bleeding and identify people who may benefit from further medical evaluation.

What are FIT-Hb and FIT-Tf?

FIT-Hb: Detecting hidden blood in stool

FIT-Hb — Fecal Immunochemical Test for Hemoglobin detects human hemoglobin in stool.

Tiny amounts of blood may be released from colorectal polyps, cancers or other gastrointestinal conditions even when the stool looks completely normal.

FIT-Hb is widely used internationally as a non-invasive colorectal cancer screening test.

It is -

• Non-invasive
• Simple stool-based testing
• Low-cost
• No bowel preparation
• No endoscopy for the initial screening
• Specific for human hemoglobin
• More convenient than traditional chemical occult blood testing
• Useful for identifying people who should undergo further evaluation

FIT-Tf: Detecting Transferrin in Stool

FIT-Tf detects human transferrin, another blood-associated protein that can be present when gastrointestinal bleeding occurs.

Transferrin can remain comparatively stable in stool and can provide additional information about occult gastrointestinal bleeding, particularly where hemoglobin from upper GI region may undergo degradation.

It has the same benefits as FIT-Hb and can complement hemoglobin-based stool testing in selected screening and clinical settings.

Important: FIT-Hb is the established stool-based test used in international colorectal cancer screening programs. FIT-Tf should be considered an additional marker of gastrointestinal bleeding rather than a replacement for diagnostic evaluation.

FIT-Hb + FIT-Tf: Looking for Hidden Bleeding from Two Markers

FIT-Hb detects human hemoglobin, FIT-Tf detects human transferrin. Together they can provide a broader approach to detecting occult gastrointestinal bleeding when evaluating possible hidden GI bleeding.

A positive result does not mean that you have cancer.

Who should consider Colorectal Cancer Screening?

You may particularly benefit from screening if you are:

45 years or older

Many international colorectal cancer screening guidelines recommend beginning routine screening for average-risk adults from around age 45.

Screening may also be considered earlier if you have:

• A family history of colorectal cancer
• Previous colorectal polyps
• A strong family history of polyps
• Long-standing inflammatory bowel disease
• Other hereditary or clinical risk factors

People with increased risk should discuss the appropriate screening method and starting age with their doctor.

Who should NOT rely on this Screening test alone?

A stool screening test is intended mainly for people who do not already have significant warning symptoms.

Do not delay medical evaluation simply to obtain a FIT test if you have:

• 🔴 Visible blood in stool
• 🔴 Black or tarry stool
• 🔴 Persistent unexplained abdominal pain
• 🔴 Unexplained weight loss
• 🔴 Persistent change in bowel habits
• 🔴 Significant unexplained anemia
• 🔴 Known colorectal cancer or a previously identified significant colorectal lesion

These situations may require direct clinical assessment and possibly colonoscopy or endoscopy.

For women, stool collection should preferably be avoided during active menstrual bleeding because contamination with blood may affect interpretation.

What if my test is Positive?

A positive result is NOT a cancer diagnosis.

Blood in stool can occur for several other reasons, including:

• Colorectal polyps
• Hemorrhoids
• Gastrointestinal inflammation
• Ulcers
• Other sources of gastrointestinal bleeding

However, a positive screening result should not be ignored.

Positive Test → Clinical Consultation → Further Investigation

Your healthcare professional may recommend:

Colonoscopy

to examine the colon and identify the source of bleeding. Depending on the clinical situation, additional gastrointestinal evaluation may also be advised.

What if the Test is Negative?

A negative result means the marker was not detected in that particular sample.

It does not provide a lifetime guarantee against colorectal cancer.

Screening works best when it is performed at the recommended intervals, and people who develop warning symptoms should seek medical evaluation even if a previous stool test was negative.

Why Screening Matters

Colorectal cancer can develop quietly.

The progression can occur over several years:

Normal colon → Polyp → Precancerous lesion → Colorectal cancer

Screening creates an opportunity to identify abnormalities before serious disease becomes clinically obvious.

That is the real value of preventive screening.

This PinkWalk, Take One More Step for Prevention

You are already walking for cancer awareness. Take another simple step toward your own preventive health.

PinkWalk 2026

3 October 2026 Kathmandu Durbar Square to Patan Durbar Square

Register • Invite • Share

🧪 FREE FIT Stool Screening

Available for 50 selected PinkWalk participants

Simple stool sample • Non-invasive • Rapid • Preventive

Walk for Awareness.

Screen for Prevention.

Act Early.

An awareness and preventive-screening initiative supported by Novala Biotech Pvt. Ltd. in collaboration with Center for American Medical Specialist (CAMS)

Stool-based blood tests are screening tools and are not intended to independently diagnose or exclude colorectal cancer. Positive results require appropriate clinical evaluation and follow-up.